UK lab space vacancy hit a record 14.3% in 2026, yet regional parks report labs near capacity. Find out why the mismatch matters.
UK Lab Space in 2026: Record Vacancy, Regional Squeeze
read more
Biotech
Redrawing the Limits of “Undruggable” Proteins
For most of modern target-based drug discovery's history, many biologically important targets have been sidelined as undruggable proteins: structural scaffolds and transcription factors with no active site to inhibit, proteins presenting flat surfaces with no pocket...
When Will Merck KGaA’s Silence Therapeutics Acquisition Close?
The Silence Therapeutics acquisition by Merck KGaA is expected to close in Q1 2027. See the terms, approvals needed and what divesiran adds.
Anktiva NHS Access: Can UK Patients Get It for Bladder Cancer?
Anktiva NHS access has no NICE recommendation behind it. The medicine holds a UK licence, but NICE ended its appraisal in June 2026 because ImmunityBio did not submit evidence.
Bispecific T-Cell Engagers in Refractory Autoimmune Disease
Bispecific T-cell engagers, originally developed to redirect immune responses against cancer, are being investigated as potential therapeutic candidates for treatment-refractory autoimmune connective tissue diseases. A 2026 study published in Nature Medicine reported...
Medicine Does Not Run on Blood Alone
Prevention-first urine diagnostics will depend not only on how accurately we can measure disease, but on how often and how easily people can be tested. Blood is medicine's default diagnostic medium for good reasons. It circulates through the whole body, carries a...
Regenerative Biologics and Biomaterials in Modern Aesthetic Surgery
The Shift Toward Regenerative Surgery When I trained, the reconstructive mindset in plastic surgery was largely mechanical. The goal was to restore form by moving tissue, removing what was damaged, or replacing what was missing, while accepting some degree of scarring...
The Future of Collagen Hydrogels in Regenerative Medicine
Collagen hydrogels are still the benchmark for regenerative medicine because they provide cells with an environment that feels biologically familiar. However, the next challenge within this field is no longer proving whether or not collagen works, but in capably...
Is RNA Potency the Problem? Creative Biolabs Webinar on saRNA Delivery
The next breakthrough in RNA therapeutics may depend less on making RNA more powerful and more on solving how efficiently it reaches and functions inside target cells. Creative Biolabs will host the upcoming webinar "Engineering saRNA Delivery Systems for...
Ivonescimab Overall Survival Win Leaves the Key Numbers Undisclosed
Akeso has reported that ivonescimab beat pembrolizumab on overall survival in a Chinese Phase III trial. HARMONi-2 is the fourth Phase III trial of ivonescimab to meet an overall survival endpoint. The ivonescimab overall survival result is the first against...
New Biology, New Opportunities in Women’s Health
Capital is moving into women’s health. But the science may give it even more reason to stay. Across the field, substantial unmet need is converging with rapidly advancing science and enormous areas of unexplored biology. Advances in genetics, molecular biology,...
Creative Biolabs’ CRISPR Cell Line Development: Plan the Validation First
CRISPR has expanded the possibilities for creating genetically defined cell models, from loss-of-function knockouts to precise knock-ins and stable Cas9-expressing systems. However, successful CRISPR cell line development depends on more than editing efficiency. The...
How Sustainability Can Become a Competitive Advantage in Biomanufacturing
Sustainability has become an expectation across the life sciences industry. Regulations are evolving, customers expect more from suppliers, and companies are making increasingly ambitious environmental commitments. Compliance has helped create a common baseline for...
Creative Biolabs’ CAR Engineering: Moving Cell Programming Inside the Body
CAR cell therapy has demonstrated that immune cells can be genetically programmed to recognize and attack disease-associated targets. Yet conventional CAR-T therapy generally depends on an elaborate ex vivo workflow involving cell collection, genetic modification,...
AI-Discovered Drugs in 2026: The State of Play
Rentosertib reaches Phase III, Isomorphic Labs raises $2.1 billion, and the EU defers its high-risk AI deadlines. What is still missing for AI-discovered drugs is an approval. AI-discovered drugs entered a different phase in 2026. One molecule has now reached a Phase...
Modeling T Cell Dysfunction: New Frontiers in Immunometabolism
While cancer immunotherapies—particularly immune checkpoint blockades (ICBs)—have transformed clinical oncology, primary and acquired resistance remain major hurdles in solid tumors. Mounting evidence reveals that this non-responsiveness is deeply tied to the...
CAR-T Therapy Explained: A Plain-English Guide
CAR-T therapy is one of the most discussed cancer treatments of the past decade, and one of the most widely misunderstood. The name is an acronym. The science involves genetic engineering. The price runs to hundreds of thousands of pounds per patient. This guide...
From Laboratory to Market: Risk Planning for Life Science Companies
The UK life sciences sector is entering an important phase of growth. The Government's Life Sciences Sector Plan sets an ambition for the UK to become the leading life sciences economy in Europe by 2030 and the third globally by 2035. It also reports that the sector...